An honest assessment of India’s position in the global AI drug discovery race
India’s AI drug discovery ecosystem is real but nascent. Roughly 30 companies – spanning startups, CRO subsidiaries, and multinational R&D centres – now apply machine learning to some stage of the drug discovery pipeline. Aggregate sector funding sits near $800 million, a fraction of China’s $5 billion-plus. Fewer than five AI-assisted molecules from Indian-led programmes have reached clinical trials, compared with 15 or more in China. The gap is structural, not intellectual.
China began building dedicated AI-pharma infrastructure – automated labs, provincial biotech clusters, targeted state capital – roughly 20 years before India moved beyond broad “AI for healthcare” rhetoric. The State Council’s 2017 AI Plan explicitly named pharmaceuticals; India’s NITI Aayog strategy of 2018 mentioned healthcare but said nothing specific about drug discovery. China’s CDE issued draft AI guidance in 2024; India’s CDSCO has published none. Beijing alone allocated over RMB 10 billion for AI-pharma in 2026. India has no equivalent line item.
Yet the conditions for rapid acceleration are falling into place. The ₹10,371-crore IndiaAI Mission (March 2024) will deploy 10,000+ GPUs for public-sector AI workloads. The National Quantum Mission earmarks ₹6,003 crore with drug design as a stated application. Genome India is building a reference catalogue of Indian genetic diversity – a dataset no Western or Chinese model can replicate. Generative AI, the most consequential shift in the field since AlphaFold, radically reduces the capital barrier to early-stage discovery by moving the bottleneck from wet-lab automation to compute and algorithms – precisely where India is strongest.
India possesses the world’s largest pool of software engineers (5 million-plus), global dominance in generic pharmaceuticals (20% of world supply, 60% of global vaccines), English-language fluency, deep Western pharma relationships, and 1.4 billion genetically diverse citizens available for clinical trials at a fraction of Western costs. Its IT service giants – TCS, Infosys, Wipro – already manage backend infrastructure for nearly every top-20 pharmaceutical company and are moving up the value chain into AI-driven R&D.
The honest assessment: India is 3–5 years behind China in AI drug discovery, not because of talent but because of infrastructure, capital, and policy focus. The optimistic assessment: generative AI is India’s inflection point. A nation that learned to be the pharmacy of the world through chemistry and cost can now compete at the frontier of drug design through compute and code. Whether it does so depends on how quickly policy catches up with potential.
India built the world’s most efficient pharmaceutical manufacturing ecosystem by mastering the art of making molecules someone else discovered. This created deep expertise in chemical synthesis, process chemistry, regulatory filing, and global distribution – but almost no experience in de novo drug discovery. AI changes this equation. The same chemical intuition that allows Indian companies to manufacture a generic at 1/10th the cost of the originator can now be paired with AI to design novel molecules from scratch.
India has 3,000+ clinical trial sites and a 1.4-billion treatment-naive, genetically diverse population. Clinical trial costs are 1/3 to 1/5 of US levels. As AI-discovered molecules move from in silico to in vivo testing, India’s clinical infrastructure becomes a critical downstream asset. The bottleneck has never been India’s ability to test drugs – it has been the absence of novel drugs to test.
“India has the chemistry to make any molecule in the world. What it has lacked is the intelligence to decide which molecules to make. AI closes that gap.”
China began building dedicated biotech parks (Zhangjiang 1992, Suzhou BioBAY 2006) decades before India considered AI-pharma infrastructure. These clusters provide integrated wet labs, shared equipment, regulatory support, and talent density. India has generic biotech parks but no AI-pharma specific zones. The physical infrastructure gap – automated labs, robotic screening, integrated data centres – cannot be closed with software alone.
China’s provincial governments compete to attract biotech companies with tax holidays, subsidised lab space, and direct equity investment. Shanghai, Suzhou, Beijing, Chengdu, and Shenzhen each operate distinct biotech cluster strategies. India’s state-level policies exist (Karnataka, Telangana) but lack the capital intensity and specificity. No Indian state has allocated the equivalent of RMB 10B to AI-pharma.
China has deployed $5B+ specifically into AI drug discovery through state-backed biotech funds, provincial allocations, and direct company investments. India’s total sector funding is ~$800M, most of it from private VCs focused on platform/SaaS models rather than asset-centric pipelines. The IndiaAI Mission ($1.24B) is broad; the National Quantum Mission ($730M) lists drug design as one of many applications. There is no $1B+ allocation specifically for AI drug discovery.
Generative AI is the great equaliser. It shifts discovery from wet labs to dry labs. India has the world’s largest software talent pool. The US BIOSECURE Act is redirecting CRO demand from China to India. English fluency enables seamless global collaboration. And India’s 1.4 billion genetically diverse citizens represent a data asset that no amount of Chinese state investment can replicate. The gap is real but the trajectory is favourable.
India’s AI drug discovery ecosystem operates through three distinct models, each reflecting different capital structures and strategic objectives.
Own molecules, own technology
Companies that build proprietary AI platforms and use them to generate internal drug pipelines. The hardest model to fund in India due to deep-tech VC scarcity.
Examples: Jubilant Therapeutics, Bugworks, Verseon (diaspora), Peptris
Sell tools, not drugs
SaaS and data infrastructure companies providing AI-powered platforms for target identification, multi-omics analysis, or computational chemistry to pharma clients.
Examples: Elucidata (Polly), Innoplexus (Ontosight), Aganitha, Cellworks
Global capability, Indian talent
Multinational pharma and CROs that locate AI/data science teams in India for cost arbitrage and access to the software talent pool. IP ownership typically resides abroad.
Examples: Novartis Hyderabad, AZ Chennai, Syngene Syn.AI, Sanofi GCC
| Company | Type | Founded | HQ | Focus | Stage | Funding |
|---|---|---|---|---|---|---|
| Jubilant Therapeutics | Pipeline | 2018 | Bedminster, NJ / Noida | Oncology (LSD1/HDAC6, PRMT5) | Phase I/II | VC-backed (Jubilant Group) |
| Bugworks Research | Pipeline | 2014 | Bengaluru / Delaware | AMR (broad-spectrum antibiotics) | Phase I | >$30M (Series B) |
| Verseon | Pipeline | 2002 | Fremont, CA (Indian-founded) | CV, oncology, ophthalmology | Phase I | Undisclosed |
| Elucidata | Platform | 2015 | Cambridge, MA / New Delhi | Multi-omics data (Polly) | Platform | $21M (Series A) |
| Innoplexus | Platform | 2011 | Frankfurt / Pune | NLP drug discovery (Ontosight) | Platform | Multi-round (undisclosed) |
| Aganitha AI | Platform | 2017 | Hyderabad / San Jose | GenAI protein engineering | Platform | Bootstrapped / seed |
| Peptris Technologies | Pipeline | 2019 | Bengaluru | AI peptide & small molecule design | Preclinical | $1M (Pre-Series A) |
| Cellworks | Platform | 2011 | Silicon Valley / Bengaluru | Biosimulation, personalised medicine | Platform | VC-backed |
| Vitas Pharma | Pipeline | 2011 | Hyderabad | AI for AMR discovery | Preclinical | Undisclosed |
| Laxai Life Sciences | Platform | 2012 | Hyderabad | Integrated AI drug discovery | Platform | Undisclosed |
| Syngene International | CRO | 1993 | Bengaluru | Syn.AI platform, integrated CRDMO | Platform | Public (Biocon subsidiary) |
| Aragen (GVK Bio) | CRO | 2000 | Hyderabad | AI hit-to-lead, ADMET | Platform | Advent International PE |
| Jubilant Biosys | CRO | 2001 | Bengaluru | AI medicinal chemistry | Platform | Jubilant Group |
| Aurigene | CRO | 2002 | Bengaluru / Hyderabad | AI-led discovery (Dr. Reddy’s) | Platform | Dr. Reddy’s subsidiary |
| Lambda Therapeutic | CRO | 2000 | Ahmedabad | Clinical CRO, AI patient recruitment | Platform | Undisclosed |
| Biocon | Generics | 1978 | Bengaluru | Biosimilars, computational modelling | Revenue $1.7B | Public (BSE/NSE) |
| Dr. Reddy’s | Generics | 1984 | Hyderabad | AI drug repurposing, Aurigene | Revenue $3.1B | Public (BSE/NSE/NYSE) |
| Sun Pharma | Generics | 1983 | Mumbai | AI manufacturing & process | Revenue $6B | Public (BSE/NSE) |
| Novartis GCC | Big Pharma | – | Hyderabad | Data science, biomarker discovery | 8,000+ employees | MNC |
| AstraZeneca GTC | Big Pharma | – | Chennai / Bengaluru | Computational modelling, analytics | Centre | MNC |
| Sanofi GCC | Big Pharma | – | Hyderabad | AI/ML R&D acceleration | Centre | MNC |
| GSK GCC | Big Pharma | – | Bengaluru | Biostatistics, ML, clinical data | Centre | MNC |
| Pfizer Hub | Big Pharma | – | Chennai / Mumbai | Clinical analytics, GenAI med-writing | Centre | MNC |
| TCS Life Sciences | IT | 1968 | Mumbai | AI drug discovery platform | Revenue $29B | Public (BSE/NSE) |
| Infosys Life Sciences | IT | 1981 | Bengaluru | Topaz GenAI, clinical AI | Revenue $19B | Public (BSE/NSE) |
| Wipro | IT | 1945 | Bengaluru | Holmes AI, drug safety analytics | Revenue $11B | Public (BSE/NSE) |
| Qure.ai | Platform | 2016 | Mumbai | Medical imaging AI (adjacent) | Platform | $40M+ |
| MedGenome | Platform | 2013 | Bengaluru | Genomics + AI target ID | Platform | $50M+ |
To understand where India stands, it helps to examine the ecosystem that is 3–5 years ahead. China’s AI drug discovery sector has matured into a clinically validated industry generating multi-billion-dollar licensing deals with global pharmaceutical companies. A detailed analysis is available at aipharmachina.com.
Chinese technology media identifies four leading AI drug discovery firms as the “Four Little Dragons of AI Drug Discovery” (AI制药四小龙): Insilico Medicine (英矽智能, HKEX: 03696), XtalPi/QuantumPharm (晶泰科技, HKEX: 02228), METiS Therapeutics (剂泰医药), and Deep Intelligent Pharma (深度智耀). Of these, Insilico Medicine is the clear market leader.
The ecosystem is top-heavy. Between 2022 and 2026, approximately 80% of AI-discovered preclinical and development candidates in the small molecule space originating from China came from a single platform provider. Multi-billion-dollar licensing deals with Eli Lilly, Sanofi, Servier, and Menarini validated the end-to-end AI discovery model. Two companies – Insilico Medicine and XtalPi – listed on the Hong Kong Stock Exchange in 2024–2025.
XtalPi (QuantumPharm) focuses on crystal structure prediction and operates robotic self-driving labs, reporting 802.6M CNY revenue in 2024. BioMap, backed by Baidu founder Robin Li, secured a $1B+ collaboration with Sanofi for biologics. DP Technology developed the Uni-Fold open-source protein structure tool. Each occupies a distinct niche in a maturing ecosystem.
For the full company-by-company analysis, deal tracker, and regulatory timeline, see the companion report at aipharmachina.com.
CRO interdependence. Chinese AI drug discovery companies have historically relied on Indian CRO infrastructure. Firms like Jubilant Biosys, Syngene International, and Aragen provide chemistry services, biological assays, and preclinical work for multiple Chinese AI-native biotechs. These collaborations remain active. Indian scientists have contributed to drug programmes across the Chinese AIDD ecosystem, and several Indian pharmaceutical companies license Chinese AI platforms for their own discovery efforts.
Regional expansion bridges. Indian companies seeking to expand into Middle Eastern markets have engaged with Chinese chemistry laboratories, using them as a bridge for regional expansion. Conversely, Chinese companies targeting South Asian markets work through Indian CRO partners. The relationship is not purely competitive – there are significant synergies, particularly in the services layer.
US-headquartered, India-built. Several prominent AI drug discovery companies are US-headquartered but have their core engineering and research teams in India. Verseon (Fremont, CA) was founded by Indian-origin physicists from Caltech and has its computational infrastructure built by Indian engineers. Elucidata (Cambridge, MA / New Delhi) runs its multi-omics platform from India. Innoplexus (Germany / Pune) operates its AI platform primarily from its Indian hub. Cellworks (San Jose / Bangalore) built its computational biology engine in India. These companies are functionally Indian but raise capital and hold IP in the US – a pattern that mirrors early Chinese biotechs before the HKEX listing reforms.
What India can learn. China’s success was built on three pillars: targeted government investment, integrated wet-lab + AI infrastructure, and aggressive licensing to global pharma. India has the software talent and the CRO base. The missing pieces are the AI-pharma government policy framework and the automated lab infrastructure. Generative AI may reduce the need for the latter, but not eliminate it entirely.
Every major multinational pharmaceutical company maintains significant capability centres in India. These are not call centres – they are data science, computational chemistry, and AI/ML hubs employing thousands of scientists and engineers. The combined headcount of Big Pharma India centres exceeds 25,000 – a shadow ecosystem of AI-pharma talent that rarely appears in startup databases.
“India’s Big Pharma centres are hidden in plain sight. Novartis alone has 8,000 people in Hyderabad doing data science and analytics. That’s more than most AI drug discovery companies have globally.”
Largest global capability centre: 8,000+ employees. Significant data science, advanced analytics, and computational chemistry workforce. Focus areas include clinical trial optimisation, biomarker discovery, and real-world evidence analysis. NIBR R&D campus closed in 2022 restructuring, but computational capabilities retained. CEO Vas Narasimhan (Indian-origin) appointed to Anthropic board in April 2026.
Global Technology Centre (GTC) pivoting heavily into AI. Initial IT focus now encompasses R&D data analytics, AI for adverse event prediction, and computational modelling support for global drug discovery teams. Expanding data science capabilities across respiratory, cardiovascular, and renal programmes.
Recently expanded Global Capacity Centre (GCC). Aggressive hiring in AI, machine learning, and data engineering. Hub focuses on digitising R&D and applying AI to accelerate pipeline development across multiple therapeutic areas.
Global Capability Center is a critical hub for tech transformation. Employs biostatisticians, ML engineers, and data scientists supporting global R&D, clinical data management, and AI-driven drug discovery support functions.
ML and analytics hubs focused on clinical trial data management, generative AI for medical writing, and predictive analytics for patient outcomes. Growing investment in AI-driven pharmacovigilance.
Bayer LifeHub focuses on digital health; data science teams collaborate globally on AI pharmacovigilance. Novo Nordisk Global Business Services hub includes massive clinical, medical, and regulatory data teams utilising AI for trial processing.
Generative AI represents a paradigm shift that aligns precisely with India’s structural advantages. Traditional drug discovery required massive capital investment in automated high-throughput screening labs – an area where the US, Europe, and China hold commanding leads. GenAI moves the bottleneck from physical infrastructure to compute and algorithms. India can compete on a level playing field in the “dry lab” space.
Virtual screening, zero-shot protein folding, and generative chemistry shift the critical resource from pipettes and robots to GPUs and code. India has few automated labs; GenAI makes that matter less.
India has 5M+ software engineers. Training them in bioinformatics is faster and cheaper than building wet labs. The tech industry downturn is pushing top ML talent toward biotech – exactly the right migration at the right time.
TCS, Infosys, and Wipro already manage IT backends for most top-20 pharma companies. They have the relationships, security clearances, and capital to lead outsourced AI drug discovery. TCS has launched dedicated drug discovery platforms; Infosys is deploying Topaz for clinical AI.
A top ML engineer costs $200K–$300K in the US. In India: $40K–$80K. Startups and global pharma can stretch R&D budgets 3–5x by building AI drug discovery teams in Bengaluru, Hyderabad, or Pune.
AlphaFold, ESMFold, RFdiffusion – foundational models are open-source. Indian startups can fine-tune for specific therapeutic areas without massive upfront compute. Cloud infrastructure (AWS Mumbai, GCP India) provides scalable access.
India’s genetic diversity is unmatched. As Ayushman Bharat digitises health records and Genome India completes sequencing, Indian AI models will discover targets that Western-centric databases miss entirely.
When an AI generates a novel molecule, someone must synthesise it. India produces 20% of global generics and 60% of global vaccines. Deep chemical synthesis expertise means AI-designed molecules can be made faster and cheaper here than almost anywhere else.
English fluency enables seamless collaboration with Western pharma HQs, frictionless consumption of global research, and natural integration into international drug development programmes. China lacks this advantage.
India’s IT services companies – with combined revenue exceeding $80 billion and over 1.5 million employees – represent a unique asset in the global AI drug discovery landscape. No other country has a comparable cluster of technology firms already embedded inside pharmaceutical R&D operations.
Revenue ~$29B · 600,000+ employees
Life Sciences practice serves 20+ pharma companies. TCS Drug Discovery platform provides computational chemistry tools. Partnership with Schrödinger for molecular modelling. Moving from backend IT to front-line AI-driven R&D support.
Revenue ~$19B · Life Sciences practice
Deploying Topaz (GenAI framework) for clinical trial data analysis. Applied AI for drug safety and pharmacovigilance. Collaborative research with IISc on federated learning for multi-centre clinical trials.
Revenue ~$11B · Holmes AI platform
Life sciences consulting with Holmes AI platform. Drug safety analytics and adverse event prediction. Expanding into computational biology capabilities for pharma clients.
Revenue ~$13B · Life Sciences practice
Computational biology capabilities growing. Life sciences practice serving pharma with data engineering, AI-driven clinical operations, and regulatory technology solutions.
The Strategic Significance: These companies already hold security clearances, compliance certifications, and deep relationships with every major pharma company. They manage the data pipelines. The pivot from IT services to AI-driven R&D services is a natural – and potentially transformative – evolution. No other country has this embedded advantage.
India’s generic pharmaceutical companies collectively generate over $15 billion in annual revenue and employ hundreds of thousands of chemists and biologists. Their AI adoption is nascent but accelerating – driven by patent cliffs, margin pressure, and the realisation that AI-enabled drug repurposing and formulation can unlock new revenue streams.
Revenue $1.7B (FY2025) · 16,545 employees · Bengaluru
India’s biosimilar leader. Founded by Kiran Mazumdar-Shaw in 1978. Computational modelling for biosimilar development and biomanufacturing scale-up. Subsidiary Syngene ($420M revenue, 5,800+ employees) provides CRO services with Syn.AI platform. The Biocon-Syngene combination represents India’s most vertically integrated AI-pharma capability.
Revenue ~$3.1B · Hyderabad
Most active of the generic giants in AI drug discovery, primarily through subsidiary Aurigene (~1,200 scientists). AI/ML adoption for drug repurposing and process optimisation. Digital transformation wing launched. Partnering with global AI firms for generic formulation development. Aurigene’s computational chemistry team is one of India’s largest.
Revenue ~$6B · India’s largest pharma · Mumbai
Limited public AI drug discovery initiatives despite being India’s largest pharmaceutical company. AI adoption focused on manufacturing quality, supply chain optimisation, and process chemistry. The gap between Sun Pharma’s scale and its AI drug discovery investment illustrates the broader industry challenge.
Combined revenue ~$8B
Cipla has AI partnerships for diagnostics (not drug discovery). Lupin uses AI for generics process optimisation. Zydus Lifesciences has explored AI for drug repurposing. No public de novo AI drug discovery programmes. These companies represent the largest untapped opportunity: massive chemistry infrastructure, regulatory expertise, and distribution networks waiting to be paired with AI-driven discovery.
India’s generic pharma companies sit on a paradox: they possess world-class chemical synthesis capabilities, regulatory expertise across 200+ countries, massive distribution networks, and deep understanding of drug metabolism – everything needed to develop novel drugs except the molecules themselves. AI drug discovery is the missing piece. The company that successfully bridges generic manufacturing expertise with AI-driven novel molecule design will transform India’s pharmaceutical industry from a $50B generics market to a competitor in the $1.5T global innovative pharma market.
India’s contract research market (~$3–4B) is a fraction of China’s (~$15–20B), but it is the country’s most direct bridge between AI drug discovery and physical drug development. The US BIOSECURE Act, targeting Chinese CROs, creates a geopolitical tailwind for Indian competitors.
Revenue ~$420M (FY2025) · 5,800+ employees · Bengaluru
India’s largest CRO. Biocon subsidiary. Syn.AI platform for computer-aided drug design and predictive ADMET. Serves top-10 global pharma. Integrating AI into SynVent integrated drug discovery workflow. The closest Indian equivalent to a WuXi-style integrated platform, though at 1/10th the scale.
Revenue ~$250M · 3,000+ employees · Hyderabad
Acquired by Advent International. Deep medicinal chemistry expertise. Aggressively deploying AI for hit-to-lead optimisation and ADMET prediction. Strong integrated chemistry-biology platform.
Revenue ~$150M · Contract research · Bengaluru
Part of Jubilant Group. AI-enhanced medicinal chemistry, biology, and DMPK services. Sister company Jubilant Therapeutics runs the pipeline arm with JBI-802 in clinical trials.
~1,200 scientists · Bengaluru / Hyderabad
Focused on oncology and inflammation drug discovery. Large computational chemistry team integrating AI/ML into hit-to-lead and lead optimisation. Functions as both a CRO and internal pipeline partner for Dr. Reddy’s.
The US BIOSECURE Act, which restricts American companies from contracting with specific Chinese biotechnology firms (primarily WuXi AppTec and BGI), creates a significant opportunity for Indian CROs. India offers comparable chemistry talent, lower costs, strong IP protection, and – crucially – geopolitical alignment with Western pharmaceutical companies. Syngene, Aragen, and Jubilant Biosys are positioned to absorb displaced demand.
India’s leader in computational biology. Departments of Computational and Data Sciences (CDS) and Biochemistry run advanced biomolecular simulations and ML models for protein-ligand interactions. Leads the Genome India Project. Collaborative work with Infosys on federated learning.
Home to the PADUM supercomputing facility, extensively used for molecular dynamics and AI-based drug design. Prof. B. Jayaram’s group developed SANJEEVINI – India’s most significant homegrown drug design software suite for automated pharmacophore-directed molecular screening.
Hosts the Robert Bosch Centre for Data Science and AI (RBCDSAA) and the Initiative for Biological Systems Engineering (IBSE). Strong work in graph neural networks for drug-target interaction prediction.
Collaborative research with TCS on GANs for de novo molecular generation. New Deloitte quantum technology facility launched April 2026 for quantum computing applications in drug design and materials science.
CSIR-CDRI (Lucknow): Central Drug Research Institute, adopting chemoinformatics. CSIR-NCL (Pune): AI for retrosynthesis. CSIR-IICT (Hyderabad): Computational chemistry tied to local CRO industry. CSIR-IGIB: MD simulations, AI for protein dynamics (Dr. Lipi Thukral).
NCBS/inStem (Bengaluru): Deep learning for protein structure and function. IIIT Hyderabad: CCNSB centre for computational biology. TIFR Mumbai: AlphaFold applications for Indian genetic disorder targets. NIPER Mohali: Network pharmacology integrating Ayurvedic knowledge with AI.
IISc, NCBS, inStem, C-CAMP incubator, Syngene campus, Biocon HQ, Electronic City biotech zone. India’s densest concentration of computational biology talent.
Genome Valley (200+ life sciences companies), CSIR-IICT, Aurigene, Aragen, IIIT Hyderabad CCNSB, Novartis GCC (8,000 employees).
IIT Delhi (SANJEEVINI, PADUM supercomputer), CSIR-IGIB, AIIMS, JNU, IIIT Delhi, Jubilant Therapeutics Noida R&D.
CSIR-NCL, TIFR Mumbai, Innoplexus Pune, IIT Bombay (Deloitte quantum facility), Haffkine Institute, Serum Institute.
Developed by Prof. B. Jayaram at IIT Delhi, SANJEEVINI is a comprehensive pharmacophore-directed algorithm for automated drug design. It represents India’s most significant indigenous contribution to computational drug discovery software – free, open-source, and used by research groups across the country. While not comparable in scale to commercial platforms like Schrödinger or Insilico Medicine’s Chemistry42, it demonstrates that foundational capability exists.
₹10,371 crore ($1.24B)
Approved March 2024
India’s largest AI investment. 10,000+ GPUs for public-sector AI workloads. Compute infrastructure, AI innovation centres, and datasets. Could enable drug discovery but has no pharma-specific vertical. Broad mandate – the question is whether drug discovery captures its fair share.
₹6,003 crore ($730M)
Approved April 2023
Drug design is a stated application area. Quantum computing for molecular simulation, docking, and materials design. Deloitte launched quantum tech facility at IIT Bombay in April 2026. Could leapfrog classical computing bottlenecks in drug discovery.
₹238 crore ($28M)
Launched 2020 · DBT / IISc
Target: 10,000 Indian genomes. Phase 1: ~3,000 completed by 2024. Creating a reference catalogue of Indian genetic diversity – critical for population-specific AI drug target identification. No comparable dataset exists for South Asian populations.
#AIforAll (2018)
114-page national strategy
Identifies healthcare as one of five priority sectors. Recommends AI Centres of Research Excellence (ACERE). Does NOT specifically mention drug discovery – focuses on diagnostics, imaging, health records. The most significant policy gap relative to China’s targeted approach.
Department of Biotechnology annual budget: ~₹3,200 crore ($380M). Funds basic research through BIRAC. BIG (Biotechnology Ignition Grant) is the primary lifeline for early-stage AI-DD startups. No dedicated AI drug discovery programme – funding is broad and competitive.
India’s Central Drugs Standard Control Organisation has published no AI-specific drug development guidelines as of 2026. China’s CDE issued draft AI guidance in 2024. The FDA has published multiple AI/ML frameworks. This regulatory silence is both a risk (no clarity for developers) and an opportunity (no bureaucratic barriers).
₹15,000 crore ($1.8B) over 6 years (2021–2028). Focused on APIs, KSMs, and complex generics manufacturing. No AI component. Drives digital transformation in chemical synthesis and process AI, but not drug discovery.
Telangana: Genome Valley (200+ life sciences companies). Karnataka: Electronic City, Biocon campus, C-CAMP incubator. Maharashtra: CSIR-NCL, Serum Institute. Tamil Nadu: IIT Madras Research Park. No AI-pharma specific zones equivalent to China’s Zhangjiang or Suzhou BioBAY.
India possesses a unique and largely untapped asset: thousands of years of documented traditional medicine (Ayurveda, Siddha, Unani) with detailed pharmacopeias of natural compounds and their observed therapeutic effects. Modern AI can systematically mine this knowledge for drug targets and lead compounds.
NIPER Mohali has published work integrating Ayurvedic knowledge with deep learning for target identification. JNU New Delhi uses AI screening of phytochemicals for metabolic disorders. The CSIR-TKDL (Traditional Knowledge Digital Library) catalogues 2.9 lakh formulations from classical Ayurvedic, Unani, and Siddha texts in patent-searchable formats.
No other country has a comparable corpus of documented traditional pharmacology. AI models can extract molecular hypotheses from these historical observations, screen computationally, and identify novel leads. This is not “alternative medicine” – it is a structured library of natural product leads waiting for modern computational validation.
The US BIOSECURE Act (2024–2025) restricts American companies from contracting with designated Chinese biotechnology companies, primarily WuXi AppTec ($4.5B revenue, 40,000 employees) and BGI Group. This legislation fundamentally reshapes global CRO supply chains.
For India, this creates a 3–5 year window:
Syngene, Aragen, Jubilant Biosys, and Aurigene are the primary beneficiaries. They offer comparable chemistry talent, strong IP protection, geopolitical alignment with the US, and costs that are competitive with (sometimes lower than) Chinese CROs. The challenge is scale: Syngene’s $420M revenue is less than 10% of WuXi’s. Indian CROs must invest aggressively in AI integration and automated lab infrastructure to absorb the redirected demand.
If India captures even 10–15% of the displaced CRO demand, it would represent $1–2B in additional annual revenue for Indian contract research – enough to fund significant AI infrastructure upgrades across the ecosystem.
A defining characteristic of India’s AI drug discovery strength is not within India at all. Indian-origin scientists, engineers, and executives occupy leadership positions at virtually every frontier AI drug discovery organisation globally. This diaspora creates a powerful bridge for knowledge transfer, investment, and talent – though IP ownership typically resides abroad. The question is whether India can convert diaspora influence into domestic capability.
Pushmeet Kohli (VP Research, Google DeepMind) – core AlphaFold leadership. Anima Anandkumar (Caltech/ex-NVIDIA) – neural operators for molecular dynamics. Dr. Vijay Pande (a16z) – Folding@home pioneer, now leading biotech VC. Adityo Prakash (Verseon) – physics-based drug design, Phase I asset.
Vas Narasimhan – CEO of Novartis, a top-5 global pharma company. Appointed to Anthropic board April 2026. Indian-origin executives hold C-suite positions across major pharmaceutical companies, creating natural bridges for AI drug discovery adoption and India-based R&D investment.
Dr. Vijay Pande at a16z is the most influential investor in GenAI drug discovery globally. Indian-origin partners at major VC firms (Sequoia, Lightspeed, Khosla) actively fund biotech. YC held its first India Startup School in Bengaluru (April 2026) – signalling growing interest in Indian deep-tech.
Diaspora influence is vast but diffuse. IP generated by Indian-origin scientists at Stanford, MIT, or DeepMind belongs to those institutions. Converting diaspora networks into domestic Indian capability requires deliberate policy – reverse brain-drain incentives, joint research programmes, and dual-country company structures.
India’s AI drug discovery ecosystem has the raw materials – talent, data, cost advantage, global connections. What it lacks is the infrastructure, capital, and policy focus that turned China from a follower into a frontier competitor in under a decade. The next four years will determine whether India’s potential converts into pipeline.
IndiaAI Mission creates dedicated pharma vertical. CDSCO issues AI guidance. 2–3 Indian AI-discovered drugs reach Phase II/III. BIOSECURE Act redirects $2B+ in CRO demand. India emerges as the “AI drug discovery back office” for global pharma, with 2–3 domestic pipeline companies achieving $1B+ valuations.
Incremental progress. CROs adopt AI tools but remain service providers. 1–2 Indian-led clinical assets. IT giants capture $500M–$1B in pharma AI services revenue. Gap with China narrows from 5 years to 3 years but does not close. Ecosystem grows organically without transformative policy intervention.
Policy remains unfocused. VC avoids deep-tech biology. Best talent continues emigrating. Indian companies remain AI-service providers with no proprietary pipelines. Gap with China widens. India becomes an AI drug discovery labour market rather than an innovation hub.
1. At least one Indian CRO (likely Syngene) will acquire or build a dedicated AI drug discovery platform comparable to WuXi’s integrated capabilities, driven by BIOSECURE demand.
2. TCS or Infosys will launch an AI drug discovery business unit generating $100M+ in annual revenue from pharma clients by 2029.
3. Genome India will expand to 50,000+ genomes and become a foundational dataset for 5–10 Indian AI drug discovery startups focused on South Asian-specific targets.
4. The first wholly India-developed AI-discovered molecule will enter Phase I clinical trials by 2028, likely from the Jubilant or Bugworks ecosystem.
5. India will not match China’s AI drug discovery output by 2030 but will establish itself as the world’s most cost-effective location for computational drug design – attracting $2–3B in outsourced AI R&D from Western pharma.
India is 3–5 years behind China in AI drug discovery. The gap is not talent – it is infrastructure, capital, and policy focus. Generative AI is the great equaliser: it shifts drug discovery from automated wet labs (where India is weak) to compute and algorithms (where India is strong). The country that became the pharmacy of the world through chemistry and cost can become a frontier in drug design through compute and code. But potential without execution is just a PowerPoint slide. The clock is ticking.
India produces abundant software engineers and abundant life scientists. The critical shortage is at the intersection: computational biologists, cheminformaticians, and ML scientists with domain expertise in drug discovery. This crossover talent is rare globally but especially scarce in India, where career tracks in software and biology rarely intersect during education.
Emerging solutions: IIT Madras IBSE, IISc CDS, and IIIT Hyderabad CCNSB now offer dedicated computational biology programmes. Private bootcamps and corporate training (TCS, Infosys) are retraining software engineers for pharma AI. But the pipeline is still early – India may produce 500–1,000 qualified bio-computational scientists per year versus the estimated need for 5,000+.
A pharma company can build an AI drug discovery team of 20 in Bengaluru for the cost of 4–5 people in Boston. This cost structure makes India the natural destination for outsourced AI R&D as the field scales.
India’s best bio-computational talent is recruited by Google DeepMind, Genentech, and US startups. Without competitive domestic opportunities, the pipeline feeds foreign ecosystems.
Indian VCs overwhelmingly fund software/fintech (18–24 month payback). AI drug discovery requires 7–10 year horizons. Without patient capital, asset-centric companies will remain underfunded.
CDSCO’s silence on AI drug guidance creates uncertainty. Companies developing AI-discovered molecules in India face unclear regulatory pathways for domestic filings.
Most India-connected AI drug discovery IP resides abroad (US, UK). CRO models transfer know-how to clients. Without strong domestic pipeline companies, India risks becoming an AI labour market rather than an innovation hub.
Despite IndiaAI Mission’s 10,000 GPU commitment, India lags in available compute for scientific workloads. Power grid reliability, data centre capacity, and GPU allocation processes remain operational challenges.
Data Sources: This report draws on public company filings (BSE, NSE, SEC EDGAR), government policy documents (NITI Aayog, DBT, DST), academic publications (PubMed, arXiv, Google Scholar), industry databases (Crunchbase, PitchBook), clinical trial registries (CTRI, ClinicalTrials.gov), patent databases (IPO India, USPTO), and direct analysis of company disclosures and press releases.
Limitations: India’s AI drug discovery ecosystem is less transparent than its Chinese or American counterparts. Many startups are bootstrapped or stealth-mode with limited public disclosure. Funding figures for several companies are estimated or undisclosed. The distinction between “AI drug discovery” and “computational chemistry with some ML” is often blurred – company self-descriptions may overstate AI capabilities. Clinical trial data for Indian-led programmes is sparse relative to mature ecosystems.
Scope: This report covers companies with significant Indian operations, founding ties, or headquarters. Diaspora-founded companies (e.g., Verseon) are included when Indian origin is material to the narrative. Multinational pharma centres are included when they maintain substantial AI/data science capabilities in India. Pure diagnostics, medical imaging, and health IT companies are excluded unless they have direct drug discovery applications.
Currency: Indian Rupee (INR/₹) figures are converted at approximately ₹83 = $1 USD unless otherwise noted. “Crore” = 10 million INR. Fiscal year references follow Indian convention (FY2025 = April 2024 – March 2025).
Estimates based on aggregate VC, government, and corporate funding in AI drug discovery. Excludes traditional pharmaceutical R&D.
Verseon, founded by Indian-origin physicist Adityo Prakash (Caltech), represents the most advanced clinical-stage programme from an Indian-diaspora AI drug discovery company. Unlike most AI-drug companies that rely on machine learning, Verseon uses physics-based computational drug design – simulating molecular interactions from first principles.
| Programme | Indication | Stage |
|---|---|---|
| VE-1902 | Strokes & Heart Attacks | Phase I |
| VE-2851 | Strokes & Heart Attacks | Preclinical |
| VE-4840 | Diabetic Vision Loss | Preclinical |
| VE-3539 | Diabetic Vision Loss | Preclinical |
| VE-4666 | Hereditary Angioedema | Preclinical |
| VE-4054 | Multidrug Resistant Cancer | Preclinical |
| VE-3771 | CD73+ve Cancer | Preclinical |
| VE-5773 | Fatty Liver Disease | Optimisation |
Leadership: CTO Sangtae Kim PhD (former VP Eli Lilly, member US NAE). Head of ML: Edward Ratner PhD (Fellow, US NAI). Founded at Caltech by Indian-origin physicists who applied astrophysics methods to molecular design.
Spun off from Jubilant Pharmova (a major Indian pharmaceutical group), Jubilant Therapeutics represents the most direct bridge between Indian pharmaceutical capital and AI-driven drug discovery. With R&D operations in Noida, it maintains the strongest India-based pipeline of any AI-driven company.